239 episodes

The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

IJGC Podcast BMJ Group

    • Science
    • 5.0 • 5 Ratings

The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

    The ALICE Trial with Glauco Baiocchi Neto

    The ALICE Trial with Glauco Baiocchi Neto

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Glauco Baiocchi. Dr. Baiocchi is the Director of the Department of Gynecologic Oncology at the AC Camargo Cancer Center in Sao Paulo, Brazil.

    Highlights:

    -SLN biopsy has emerged as an accurate method for lymph node staging in endometrial cancer.
    -Prospective studies aimed to analyze the performance of SLN biopsy in staging endometrial cancer rather than oncological outcomes.
    -ALICE trial aims to confirm that SLN mapping without systematic node dissection does not negatively impact oncological outcomes.

    • 33 min
    Mentor's Podcast: Jalid Sehouli

    Mentor's Podcast: Jalid Sehouli

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Jalid Sehouli. Dr. Sehouli is director of the department of gynecology with center of oncological surgery at Charité Medical University in Berlin. He founded the first certified ovarian cancer center in 2007, published more than 500 articles, and is a teacher and a writer of several belletristic books.

    Highlights:
    Gynecology should be always holistic, interdisciplinary, and multi-professional.
    Research in gynecology relies on teamwork, and international collaboration is essential.
    The most relevant drug in medicine is communication!

    • 1 hr 10 min
    Gender Imbalance in Authorship in Gynecologic Oncology

    Gender Imbalance in Authorship in Gynecologic Oncology

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Sarah Mah to discuss the gender imbalance in authorship in gynecologic oncology. Sarah Mah is a Gynecologic Oncology fellow at McMaster University who received her MSc in Quality Improvement and Patient Safety through the University of Toronto Institute of Health Policy, Management and Evaluation and completed residency at the University of British Columbia. Her research interests are in quality improvement with an equity and sustainability lens, knowledge translation, and cancer prevention.

    Highlights:
    Women now account for 55-70% of practicing Gynecologic Oncologists and >80% of Gynecologic Oncology fellows in the United States and Canada.
    Rates of female first authorship in Gynecologic Oncology journals are rising in proportion, but rates of female senior authorship lag behind, with male authors still overrepresented.
    Women remain underrepresented as members of Editorial Boards of Gynecologic Oncology journals, particularly in leadership positions.
    While the COVID-19 pandemic has not yet impacted the proportion of female authors, we discuss reasons for why this could be of future concern and the importance of ongoing surveillance.
    We discuss some of the literature regarding gender inequity in academia and publishing and explore possible strategies for improvement.

    • 24 min
    Secondary Cytoreductive Surgery in Ovarian Cancer

    Secondary Cytoreductive Surgery in Ovarian Cancer

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Robert Bristow, Prof. Christina Fotopoulou, and Dr. Myong Cheol Lim to discuss Secondary Cytoreductive Surgery in Ovarian Cancer. Dr. Bristow is Professor and Chair of the Department of Obstetrics and Gynecology at the University of California, Irvine School of Medicine. His clinical expertise and research interests focus on the surgical management of advanced-stage and recurrent ovarian cancer. Prof. Christina Fotopoulou has served as the Chair of Gynaecological Cancer Surgery at the Department of Surgery and Cancer at Imperial College London, UK. She has served as an elected ESGO council member and Chair of the ESGO guidelines committee. Dr. Myong Cheol Lim is a gynecologic oncologist, working for National Cancer Center Korea. He is fully dedicated to clinical research, including cytoreductive surgery and HIPEC for the management of ovarian cancer.

    Highlights:
    - This large meta-analysis on the value of secondary debulking showed that both complete as well as optimal cytoreductive surgery for ovarian cancer relapse significantly increased patients' overall survival.
    - Median overall survival of a patients cohort increased by 9% and 7% when the complete and optimal cytoreductive rates increased by 10%, respectively, even after adjusting of other well established prognostic factors.
    - Patients with ovarian cancer relapse should be evaluated for their eligibility for secondary debulking surgery in an effort to improve their survival.

    • 44 min
    The PARCER Trial with Supriya Chopra

    The PARCER Trial with Supriya Chopra

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Supriya Chopra. Dr. Chopra is a Professor in Radiation Oncology at ACTREC, Tata Memorial Centre and Principal Investigator of the PARCER trial. Her research focus is to improve outcomes of cervical cancer through use of advanced radiation techniques in patients undergoing RT for both primary and recurrent metastatic cervical cancer. She also co-leads multi-institutional molecular translational research programme (BIOEMBRACE) for cervix cancer.

    HIGHLIGHTS:
    - Postoperative Adjuvant Radiation in Cervical Cancer (PARCER), a phase III randomized trial, compared late toxicity after image-guided intensity-modulated radiotherapy (IG-IMRT) with three-dimensional conformal radiation therapy (3D-CRT) in women with cervical cancer undergoing postoperative radiation.
    - IG-IMRT results in reduced toxicity with no difference in disease outcomes in cervical cancer.
    - The 3-year cumulative incidence of grade ≥ 2 late GI toxicity in the IG-IMRT and 3D-CRT arms were 21.1% versus 42.4%.
    - The cumulative incidence of grade ≥ 2 any late toxicity was 28.1% versus 48.9%.
    - Patients reported reduced diarrhea (P = .04), improved appetite (P = .008), and lesser bowel symptoms (P = .002) with IG-IMRT.
    - The 3-year pelvic relapse-free survival and disease-free survival in the IG-IMRT versus the 3D-CRT arm were 81.8% versus 84% and 76.9% versus 81.2%, respectively.

    • 40 min
    Updates and New Options in Advanced Ovarian Cancer

    Updates and New Options in Advanced Ovarian Cancer

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Katherine Kurnit. Dr. Kurnit is an Assistant Professor at the University of Chicago in the section of Gynecologic Oncology. Her research interests include developmental therapeutics and early phase clinical trials for patients with gynecologic cancers.

    Highlights:
    Although surgical practices have changed over time, there is still much debate and no consistent consensus about timing or the use of new therapies such as HIPEC.
    More options for upfront maintenance therapy are now available for ovarian cancer patients.
    We need new treatment approaches for patients with platinum-resistant ovarian cancer.
    Finding ways to ensure ovarian cancer care is safe, feasible, and cost-effective in many different settings (nationally and internationally) will be important.
    New strategies for screening and prevention are sorely needed

    • 26 min

Customer Reviews

5.0 out of 5
5 Ratings

5 Ratings

Top Podcasts In Science

BBC Radio 4
BBC Radio 4
Sam Harris
Jordan Harbinger
Hidden Brain
Stak

You Might Also Like

Various
The Society of Gynecologic Oncology
K. Mueller
Dr Neil Love
Brown Ob/Gyn Residency
Elizabeth Day and Emma Reed Turrell